Vanguard Group Reports 0% Stake in Regeneron Due to Internal Realignment
REGENERON PHARMACEUTICALS, INC.
Subscribe to track REGN
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Vanguard Group Reports 0% Stake in Regeneron Due to Internal Realignment
Company: REGENERON PHARMACEUTICALS, INC. Form: SCHEDULE 13G/A | Filed: 2026/03/27 Significance: Low (Administrative)
Insider: The Vanguard Group Title: Institutional Investor | Relationship: Investment Adviser
Ownership Update: • Shares Owned: 0 • Percent of Class: 0% • Reason: Internal corporate realignment (Subsidiaries reporting separately)
Key Insight: The Vanguard Group, Inc. reports 0 beneficial ownership due to an internal realignment. Subsidiaries will now report holdings separately. This does not indicate a market liquidation of shares.
Market Context: Regeneron has a Market Cap of $77.47B. This filing is technical in nature and reflects a change in reporting structure rather than a change in market sentiment.
Comprehensive Analysis
SEC Filing Analysis: REGENERON PHARMACEUTICALS, INC.
Executive Summary
- Trading Significance: Low
- Key Takeaway: The Vanguard Group reports 0% ownership due to an administrative realignment where subsidiaries now report separately; this is not a liquidation.
- Market Impact: Neutral - The underlying assets likely remain within Vanguard subsidiaries, limiting market supply shock.
Company Information
| Field | Value |
|---|---|
| Company | REGENERON PHARMACEUTICALS, INC. |
| CIK | 0000872589 |
| Industry | Pharmaceutical Preparations |
| Market Cap | $77.47 Billion |
Insider Information
| Field | Value |
|---|---|
| Name | The Vanguard Group |
| CIK | 0000102909 |
| Type | Institutional Investment Adviser |
| Relationship | Former >5% Owner |
Transaction Details
| Field | Value |
|---|---|
| Form Type | SCHEDULE 13G/A |
| Event Date | 03/13/2026 |
| Shares Owned After | 0 |
| Percent of Class | 0% |
| Ownership Type | N/A |
Financial Impact Assessment
Transaction Materiality
| Metric | Value |
|---|---|
| Market Cap | $77.47 Billion |
| Shares Outstanding | 105,720,000 |
| Reported Ownership | 0 shares (0.00%) |
| Materiality Assessment | Low (Administrative Change) |
Impact Evaluation
- Market Cap Context: While Vanguard is a major holder, this specific filing indicates a transfer of reporting responsibility to subsidiaries rather than a sale of $77B+ worth of stock.
- Ownership Concentration: The filing indicates The Vanguard Group, Inc. (parent) no longer holds the securities directly for reporting purposes.
- Transaction Significance: The reduction to 0% is technical. The footnote explicitly states: "Certain subsidiaries... will report beneficial ownership separately... The Vanguard Group, Inc. no longer has... beneficial ownership over securities beneficially owned by such subsidiaries."
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: The filing details confirm this is an internal restructuring of reporting lines (SEC Release No. 34-39538) rather than a bearish exit. No selling pressure is anticipated from this specific event.
Volume & Sentiment
- Expected Volume Impact: Negligible.
- Sentiment Indicator: Neutral. Algorithms reading the headline "0% ownership" might react briefly, but human analysis confirms no fundamental change in institutional support.
Additional Context
Transaction Notes
- Special Circumstances: The filing cites an internal realignment effective January 12, 2026. This is a compliance update to reflect that Vanguard subsidiaries are now filing as distinct entities.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.